Tag: GlobeNewswire

First Patient Dosed with JOTROL^™ Marks Major Clinical Milestone for Jupiter Neurosciences’
Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL^™ in Patients with Parkinson’s Disease

Tungsten Advisors has been retained to identify strategic options to monetize Jupiter’s existing clinical development programs via corporate partners and explore other strategic options for a transaction to maximize shareholder value

Jupiter, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for neurodegenerative diseases, today announced that the first patient has been dosed in the company’s Phase 2a RESET clinical trial evaluating JOTROL^™ in patients with Parkinson’s disease (PD).

The dosing of the first patient represents an important clinical milestone for Jupiter and marks the transition of JOTROL^™ into Phase 2a clinical evaluation in patients with Parkinson’s disease. The RESET study (NCT07592767) is a multicenter, randomized, double-blind, placebo-controlled Phase 2a clinical trial designed to evaluate the safety, tolerability, pharmacokinetics and biomarker effects of JOTROL^™, Jupiter’s investigational, proprietary micellar formulation of trans-resveratrol.

“Dosing the first patient in RESET is a significant milestone for Jupiter and the culmination of years of scientific, regulatory and clinical development work,” said Christer Rosén, Chief Executive Officer of Jupiter Neurosciences. “We believe that JOTROL has the potential to address biological pathways implicated in Parkinson’s disease, including mitochondrial dysfunction, oxidative stress and neuroinflammation. With patient dosing now underway, we look forward to advancing enrollment and generating clinical data that will help us evaluate JOTROL’s potential in this significant area of unmet medical need.”

RESET is expected to enroll approximately 30 patients with Parkinson’s disease who will be randomized 1:1:1 to receive one of two dose levels of JOTROL^™ or placebo. Study treatment will be administered orally for 12 weeks. The trial’s primary objectives include assessment of safety, tolerability and pharmacokinetics, including evaluation of JOTROL^™ exposure in plasma and cerebrospinal fluid. Secondary and exploratory assessments include biomarkers associated with energy metabolism, inflammation and Parkinson’s disease, as well as clinical outcome measures.

“The first patient dosed in RESET represents an important step in translating the scientific rationale for JOTROL into a clinical study in people living with Parkinson’s disease,” said the study’s principal investigator Fernando L. Pagan, MD, professor of neurology at Georgetown University School of Medicine and Vice Chairman of the Department of Neurology. Georgetown University is the study sponsor. “This study is designed to provide important information regarding JOTROL’s safety, pharmacokinetics and biological activity in Parkinson’s disease and to help inform the future clinical development of the program.”

JOTROL^™ is designed to overcome limitations associated with the bioavailability of conventional resveratrol. In a completed Phase 1 study in healthy volunteers, JOTROL^™ demonstrated increased systemic exposure to resveratrol and measurable cerebrospinal fluid concentrations. The Phase 1 study reported no serious adverse events. Preclinical studies in a model of Parkinson’s disease also demonstrated neuroprotective effects, including improvements in measures of motor function. These findings supported advancement of JOTROL^™ into the RESET Phase 2a study.

“Moving from enrollment to dosing our first patient is a defining moment for Jupiter and, importantly, puts us in a position to begin generating patient data from our lead clinical program,” said Alison Silva, President and Chief Business Officer of Jupiter Neurosciences. “We are grateful to the patients, investigators, clinical sites and collaborators participating in RESET. We remain focused on efficient execution of the study and look forward to providing updates as the program progresses.”

As the company continues to enroll patients in the RESET trial, it has also initiated a formal process to explore and evaluate strategic options to maximize shareholder value. These options may include the sale or licensing of clinical and other assets, strategic partnerships, business combinations, or other corporate transactions.

Jupiter has engaged Tungsten Advisors as the company’s strategic advisor. There can be no assurance that this process will result in any transaction. Jupiter does not intend to provide updates regarding the process unless and until its Board of Directors approves a specific transaction or the Company otherwise determines that disclosure is appropriate or required.

About Parkinson’s Disease Market

• 1.1 million U.S. patients living with Parkinson’s Disease https://www.parkinson.org/understanding-parkinsons/statistics
• 90,000 new U.S. diagnoses annually; 1.2 million U.S. patients projected by 2030 https://www.parkinson.org/understanding-parkinsons/statistics
• $82.2 billion annual U.S. economic burden of Parkinson’s Disease https://www.parkinson.org/understanding-parkinsons/statistics
• ~90% of PD patients are Medicare-enrolled https://data.cms.gov/summary-statistics-on-beneficiary-enrollment
• No disease-modifying therapies currently approved for PD; multiple investigational candidates are in active development by other companies https://www.accessdata.fda.gov/scripts/cder/daf
• Global PD treatment market: $5.65B (2024) → $7.58B (2030), CAGR 5.04% https://www.grandviewresearch.com/industry-analysis/parkinsons-disease-drugs-market
• Global prevalence: >10 million patients https://doi.org/10.1016/S1474-4422(18)30295-3

About the RESET Trial

RESET (RESvEraTrol in Parkinson’s Disease) is a multicenter, randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating JOTROL^™ in approximately 30 patients with Parkinson’s disease. Participants are randomized to receive one of two doses of JOTROL^™ or placebo over a 12-week treatment period.

The study is designed primarily to evaluate safety, tolerability and pharmacokinetics and will also examine pharmacodynamic and disease-relevant biomarkers, including measures associated with mitochondrial function, energy metabolism and inflammation. Exploratory clinical assessments are intended to provide additional information to inform the design of future JOTROL^™ clinical studies. Additional information regarding RESET is available at ClinicalTrials.gov under identifier NCT07592767. Dr. Charbel Moussa, a sub-investigator on this study at Georgetown University, has financial interests related to Jupiter Neurosciences. 

About JOTROL^™

JOTROL^™ is Jupiter Neurosciences’ proprietary and patented micellar formulation of trans-resveratrol designed to improve the bioavailability of resveratrol. Resveratrol has been extensively studied for its potential effects on biological pathways associated with oxidative stress, inflammation and mitochondrial function. Jupiter is developing JOTROL^™ as an investigational therapeutic candidate for neurodegenerative and rare diseases.

JOTROL^™ is an investigational drug candidate and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority. Its safety and efficacy for the treatment of Parkinson’s disease or any other disease have not been established.

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company’s lead program, JOTROL^TM – a proprietary, enhanced bioavailability resveratrol formulation – is currently in a Phase 2a clinical trial for Parkinson’s disease. JUNS also commercializes Nugevia^TM, a consumer longevity supplement. Additionally, the Company’s pipeline includes ALA-002, a next-generation, patented psychedelic new chemical entity (NCE) recently in-licensed from PharmAla Biotech Holdings. For more information, please visit www.jupiterneurosciences.com.

Forward-Looking Statements

Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, without limitation, statements regarding the company’s pursuit of strategic options; patient enrolment and dosing timelines for the Phase 2a RESET trial; expected study completion dates; expected development timelines; and potential regulatory pathways. These forward-looking statements are often indicated by terms such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “likely,” “look forward to,” “may,” “objective,” “plan,” “potential,” “predict,” “project,” “should,” “slate,” “target,” “will,” “would” and similar expressions and variations thereof. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Jupiter’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, that clinical trials may not demonstrate adequate safety or tolerability; enrolment may be slower than anticipated; preliminary data may not be predictive of future results; the company’s inability to identify or consummate strategic opportunities on the terms contemplated or at all; and other risks, uncertainties and other factors described under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed on April 1, 2026 and any subsequent quarterly reports. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Investors are cautioned not to place undue reliance on forward-looking statements. We assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Investor Relations Contact
Jupiter Neurosciences, Inc.
Christer Rosen, Chairman & Chief Executive Officer
ir@jupiterneurosciences.com

CHIHUAHUA, Mexico, Oct. 06, 2026 (GLOBE NEWSWIRE) — GCC, S.A.B. de C.V. (BMV: GCC*), cement, aggregates and concrete in the United States and Mexico, will host a conference call to review its third quarter 2026 earnings results on Wednesday, October 28 at 11:00 a.m. (ET). Earnings results for the quarter ended September 30, 2026, will be released on Tuesday, October 27, after market close.

The call will be hosted by Enrique Escalante, CEO, and Maik Strecker, CFO, and can be accessed by dialing +1 (877) 407 0789 or +1 (201) 689 8562 for international calls. The conference ID is 13757650.

The presentation and listen-only webcast will be available via the following link.

A replay of the webcast will be available the same day at 2:00 p.m. (ET) until November 4 at 11:59 p.m. (ET). The replay can be accessed through this link or by dialing +1 (844) 512 2921 or +1 (412) 317 6671 for international calls. The replay PIN is 13757650. Additionally, an online replay of the live broadcast will be available on the Company’s website two days later.

For more information visit www.gcc.com or contact:

GCC Investor Relations
Sahory Ogushi
MX +52 (614) 442 3176
US + 1 (303) 739 5943
soguship@gcc.com

About GCC

GCC is a leading supplier and producer of cement, aggregates, concrete and construction‐related services in the United States and Mexico, with an annual cement production capacity of 7 million metric tons. Founded in 1941, the Company’s shares are listed on the Mexican Stock Exchange under the ticker symbol GCC*.

Consolidated harvest volumes:

	Q3 2026
Farming Central Norway	51.4
Farming Northern Norway	48.5
SalMar Ocean	0
Icelandic Salmon	5.2
Totalt	105.1

All figures in 1,000 tons gutted weight. 

Harvest volumes in Central Norway were affected towards the end of the quarter by harvesting due to ISA and fish welfare considerations, which impacted cost development during the period.

The full Q3 2026 report will be released on Tuesday 3 November 2026 at 06:30 CET, the following presentation will be available through Norwegian webcast at 08:00 CET and English webcast (recording) at 10:00 CET.

For more information, please contact:
Håkon Husby
Head of IR
Tel: +47 936 30 449
Email: hakon.husby@salmar.no

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act

Vancouver, BC, Canada, Oct. 06, 2026 (GLOBE NEWSWIRE) — Bear Gold Corp. (TSXV: BEAR) (the “Company” or “BEAR”) announces that its common shares are expected to resume trading on the TSX Venture Exchange (the “TSXV”) at market open on Thursday, October 8, 2026.

Trading in the Company’s common shares was halted on September 28, 2026, pending the announcement of the Company’s acquisition of an optioned interest in the Peerless Property.  As announced, the Company has entered into an assignment and assumption of property option agreement dated September 25, 2026, with Bathurst Metals Corp. (“BMV”) and Stanley R McClay as bare trustee for BCT Holdings Corp., pursuant to which the Company will acquire BMV’s 100% optioned interest in the Peerless Property located in the Bridge River Mining Camp, British Columbia.  This transaction is subject to TSXV approval.

Full details of the transaction are set out in the Company’s news release dated October 1, 2026.

About Big Bear Gold Corp.

Big Bear Gold Corp. is focused on acquiring and developing mineral properties with strong potential to host significant resources in Western Canada. We are looking for additional projects that are in an established mining district with highly prospective geology that could host significant resources.

ON BEHALF OF THE BOARD OF DIRECTORS
“Peter Laipnieks”
Peter Laipnieks, President & CEO

Contacts:
Big Bear Gold Corp.
Suite 900, 570 Granville Street
Vancouver, BC  V6C 3P1

Investor Relations: (250) 216.5674
Email:  bigbeargold007@gmail.com
Website: bigbeargold.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking information
All statements included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements.  Forward-looking statements are frequently identified by such words as “may”, “will”, “plan”, “expect”, “anticipate”, “estimate”, “intend” and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management.  These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances.  In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will prove inaccurate, certain of which are beyond the Company’s control.  Actual events or results may differ materially from those projected in the forward-looking statements and the Company cautions against placing undue reliance thereon. 

The Company believes that the expectations reflected in forward-looking statements included herein are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking statements included herein should not be unduly relied upon.  These statements speak only as of the date hereof.  The Company does not intend, and does not assume any obligation, to revise or update these forward-looking statements, except as required by applicable law.

TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz, LS Exchange, TTMzero, Düsseldorf and Quotrix Düsseldorf Stock Exchanges and GLBXF – OTCQX International in the US) is pleased to inform shareholders that LaFleur Minerals Inc. have reported drill results from the Bartec portion of the Swanson Property in Barraute Township, Quebec upon which Globex retains a two percent (2%) Gross Metal Royalty (GMR).

Hole SW-26-124 returned 6.05 g/t Au over 8m (26.2ft) including 14.96 g/t Au over 3.0 m (9.8 ft) from in-hole depths of 38.0 m to 46.0 m.   True width has yet to be determined as this is the first modern-day drill hole in the gold occurrence.

Shareholders can access the Lafleur press release by clicking here.

Sampling, QAQC, and Laboratory Analysis Summary

All core logging and sampling completed by LaFleur Minerals as part of its diamond drilling program was subject to a strict standard for Quality Control and Quality Assurance (QAQC), which included the insertion of certified reference material (standards), blank materials, and field duplicate analysis. NQ-diameter sawed half-core samples from the drilling program at Bartec were securely sent by Company geologists to AGAT Laboratories Ltd. (AGAT), with sample preparation in Val-d’Or, Québec and analysis in Thunder Bay, Ontario,

The LaFleur Qualified Person notes no drilling, sampling or recovery factors that could materially affect the accuracy or reliability of the data.

Jack Stoch, P.Geo., Executive Chairman and CEO of Globex, in his capacity as a Qualified Person (Q.P.) under Ni 43-101, prepared the information that forms the basis of this written disclosure.

We Seek Safe Harbour.	Foreign Private Issuer 12g3 – 2(b)
	CUSIP Number 379900 50 9 LEI 529900XYUKGG3LF9PY95
For further information, contact:
Jack Stoch, P.Geo., Acc.Dir. Executive Chairman & CEO Globex Mining Enterprises Inc. 120 Carlton Street, Unit 219 Toronto, Ontario, Canada M5A 4K2	Tel.: 819.797.5242 Fax: 819.797.1470 info@globexmining.com www.globexmining.com

Caution Regarding Forward-Looking Statements

Certain statements included in this press release may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. Except as may be required by such laws, Globex Mining Enterprises Inc. (“Globex”) does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements, by their very nature, are subject to numerous risks and uncertainties. As a result, actual results could differ materially from Globex’s expectations expressed in or implied by such forward-looking statements. No assurance can be given that any events anticipated by the forward-looking statements will materialize, or if any of them do, what benefits Globex will derive therefrom. Numerous risk factors which may cause actual results to differ materially from expectations expressed in or implied by the forward-looking statements are discussed in Globex’s annual information form for the 2025 fiscal year filed with the Canadian securities regulatory authorities, available on SEDAR+ at www.sedarplus.ca and on Globex’s website at www.globexmining.com. Globex cautions readers that such risks are not the only ones that could impact it. Additional risks and uncertainties not currently known to Globex or that Globex currently deems to be immaterial may have a material adverse effect on Globex’s business, financial condition, and results of operations. Given these risks and uncertainties, Globex cautions investors and others against placing undue reliance on such forward-looking statements as a prediction of future results or for any other purpose. This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the Securities Act of 1933, as amended (the “1933 Act”), or with any securities regulatory authority of any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, within the United States or to, or for the account or benefit of, U.S. persons (as such term is defined in Regulation S under the 1933 Act), except pursuant to an exemption from or in a transaction not subject to the registration requirements of the 1933 Act.

BROSSARD, Quebec, Oct. 06, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, provides an update on the stock warrants that were exercised and that have expired in the last two months (the “Period”), as well as the outstanding balance.

During the Period, 3,218,333 stock warrants were exercised for gross proceeds of $1,287,333.

During the Period, the following stock warrants have expired.

Number of warrants	Issue date	Original expiry date	Amended expiry date
1,414,286	February 27, 2024	August 27, 2025	August 5, 2026
650,000	March 22, 2024	September 22, 2025	August 5, 2026
1,125,000	May 9, 2024	November 9, 2025	August 5, 2026
3,502,931	June 5, 2024	December 5, 2025	August 5, 2026
8,333,333	September 20, 2024	March 20, 2026	September 5, 2026
2,655,691	October 25, 2024	April 25, 2026	September 25, 2026

As at the date of this press release, the following stock warrants are outstanding and can be exercised at the price of $0.40 per common share.

Number of warrants	Issue date	Original expiry date	Amended expiry date
6,715,369	February 5, 2025	August 5, 2026	June 5, 2027
13,494,459	December 5, 2025	June 5, 2027	n/a
513,248	December 5, 2025	June 5, 2027	n/a

DIAGNOS would like to thank the shareholders for their continuous support.

The currency stated in this press release is the Canadian dollar.

About DIAGNOS
DIAGNOS is a public Canadian corporation dedicated to the early detection of critical eye-related health problems. DIAGNOS manufactures CARA System, a software platform which assists health specialists in the detection of retinal eye pathologies. CARA System is currently licensed for commercialization in Canada and Saudi Arabia. By developing innovative products based on AI technologies, DIAGNOS’ solutions provide healthcare clinicians with valuable information that refines diagnostic accuracy, streamlines workflows, and improves patient outcomes.

Additional information is available at www.diagnos.com and www.sedarplus.com.

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information, please contact:

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Davidson Kempner Capital Management LP
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	easyJet plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	05/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	27 2/7p ordinary (ISIN-GB00B7KR2P84)
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:
(2)   Cash-settled derivatives:	16,772,528	2.21%
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	16,535,013	2.21%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
27 2/7p ordinary	CFD	Increasing a long position	236,891	GBP 6.7600
27 2/7p ordinary	CFD	Increasing a long position	624	GBP 6.7615

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii)        Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	06/10/2026
Contact name:	Alex McMillan
Telephone number:	646 282 5805

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Viridien

A French société anonyme
with a share capital of € 7,219,747
Registered office: 27 avenue Carnot, 91300 Massy, France
Evry Trade and Companies Register 969 202 241

Information on the total number of voting rights and shares

Pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial markets authority
(AMF- Autorité des Marchés Financiers)

Date of the information	Total number of issued shares	Number of actual voting rights*	Number of theoretical voting rights**
September 30, 2026	7,219,747	7,255,970	7,256,219

*         All of the Company shares have the same voting rights, except for treasury shares which do not have voting rights and registered shares held for more than two years, which have double voting rights.

**         Pursuant to Article 223-11 of the General Regulation of the French Financial markets authority, the number of theoretical voting rights is calculated based on the shares having either single or double voting rights, including treasury shares which are deprived of voting rights.

Attachment

• 2026.09.30_information mensuelle AMF ENG

On 06.10.2026 the Lithuanian Competition Authority refused to accept the application of the company’s parent company MM Grupp OÜ (MMG) to resolve the acquisition issue of the cinema located in the Vilnius Akropolis center by granting a merger clearance.

This is a side episode in the main dispute between MMG and the Authority, which is pending in the Lithuanian court, concerning the acquisition of the Vilnius Akropolis cinema and the Kaunas cinema by MMG, and the reason for which is the surprising and retroactive illegal change of the established practice by the Authority. MMG sold both acquired cinemas to the company, from which the Vilnius cinema is currently operated by the company, and regarding the Kaunas cinema, the transaction between the company and MMG was reversed in order to mitigate the company’s risks.

On 28.10.2026, the Authority ruled that MMG acquired these 2 cinemas without a merger permit and must now apply for a merger permit retrospectively. MMG challenged the Authority’s decision in court, because the acquisition did not require a merger permit and in parallel submitted a merger application to the Authority regarding the Vilnius cinema in order to resolve the Vilnius cinema issue more quickly (the litigation will take years).

Now the Authority has refused a faster solution regarding the Vilnius cinema, and the issue regarding both cinemas remains for the court to decide.

Additional information:
Toomas Tiivel
Chairman of the Management Board
+372 550 5285

toomas.tiivel@apollogroup.ee

WISeSat Announces $10 Million PIPE Investment Led by SEALSQ to Accelerate Space Cybersecurity and Post-Quantum Communications

Investment to strengthen WISeSat’s cybersecurity offering, support a new generation of satellites, and advance secure end-to-end post-quantum communications for sovereign space transactions

GENEVA, Switzerland, October 6, 2026 – WISeSat.Space Holdings Corp. (Nasdaq: SAIQ) (“WISeSat.Space”), a space technology company, today announced the closing on October 1, 2026, of a $10 million private investment in public equity (PIPE) by SEALSQ Corp (NASDAQ: LAES) (“SEALSQ”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products. WISeSat.Space and SEALSQ are subsidiaries of WISeQey Corp. (formerly known as WISeKey International Holding AG, “WISeQey”) (Nasdaq/SIX: WQEY), a global quantum cybersecurity and space IoT company.

The investment provides WISeSat.Space with additional equity capital as it advances it space cybersecurity strategy, including the planned expansion of its satellite infrastructure, and the integration of post-quantum cryptography (PQC) security technologies into its satellites, ground and user-segment architectures.

WISeSat.Space is engaged in the development of a new generation of WISeSat.Space satellites, intended to support trusted communications, digital identity, and data exchange through space-based infrastructure. The planned architecture is intended to integrate advanced cybersecurity capabilities with satellite communications, creating a foundation for trusted and resilient communications across space and ground infrastructure.

A key focus of the program is expected to be the development of quantum-resilient secure communications capabilities, designed to address emerging cybersecurity threats associated with the future evolution of quantum computing. By incorporating post-quantum security into the satellite communications architecture, WISeSat aims to strengthen device authentication, data integrity, and secure communications across space and ground infrastructure.

The collaboration with SEALSQ is also expected to support the development of a broader trusted space infrastructure, under which WISeSat.Space would provide satellite capacity and related space and ground infrastructure, while SEALSQ would use that capacity to support the development and delivery of planned quantum and post-quantum services using its secure semiconductor, cryptographic and trusted identity technologies.

Carlos Moreira, CEO of WISeSat.Space, SEALSQ and WISeQey noted, “This investment brings together two companies within the WISeQey group around a shared goal: making space infrastructure secure against both current and future cyber threats. For WISeSat.Space, it provides capital to advance our next generation of satellites and to build post-quantum security into our space, ground and user segments. For SEALSQ, it opens a path to deliver quantum and post-quantum services using WISeSat.Space’s satellite capacity. Together, secure semiconductors, cryptography and satellite connectivity have the potential to help set new standards for trust and security across the emerging space economy.”

Gwenael Rouy-Poirier, CFO of WISeSat.Space, added, “Capital is only valuable if it translates into execution. This $10 million investment strengthens our balance sheet as we move into the next phase of WISeSat.Space’s development. Our focus is disciplined capital allocation as we advance the satellite infrastructure, post-quantum security integration and industrial partnerships required to build a scalable business. We intend to deploy this capital carefully, prioritizing the investments that move us closer to delivering secure, revenue-generating space services and long-term value for our shareholders.”

The new satellite program is expected to contribute to WISeSat.Space’s broader vision of bringing trust and sovereignty to space transactions, enabling secure interactions among independently operated space and terrestrial systems while strengthening the protection of critical digital assets.

The PIPE Investment closed on October 1, 2026, concurrently with the closing of the Business Combination.  The purchase price per share, equal to the redemption price, was $10.79 per share.  The Subscription Agreement includes a price-protection mechanism that may result in the issuance of additional WISeSat Ordinary Shares to SEALSQ under certain conditions if the volume-weighted average price of WISeSat Ordinary Shares for the 10 consecutive trading days ending on the 60th calendar day after Closing is below the purchase price, subject to a maximum issuance of an additional 1,073,216 shares. SEALSQ is also subject to customary lock-up restrictions under the Subscription Agreement.

About WISeQey

WISeQey Corp. (“WISeQey”), is a British Virgin Islands holding company focused on post quantum cybersecurity, digital identity, space technology and the Internet of Things (IoT). Its operating subsidiaries and technology platforms address distinct parts of this portfolio:

1. SEALSQ Corp (Nasdaq: LAES) develops secure semiconductors, public key infrastructure (PKI) and post-quantum security products.
2. WISeSat.Space (Nasdaq: SAIQ) develops space technology and secure satellite communications, particularly for IoT applications.
3. WISeID provides digital identity, authentication, secure access and digital signing for individuals, enterprises and connected devices.
4. WISe.ART Corp operates the WISe.ART marketplace, which uses blockchain technology to support trusted digital asset and NFT transactions.
5. SEALCOIN AG develops decentralized physical infrastructure network (DePIN) technology and the SEALCOIN platform.

Each subsidiary contributes to WISeQey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeQey platform. WISeQey secures digital identity ecosystems for individuals and objects using blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeQey plays a vital role in securing the Internet of Everything. Trusted by the OISTE/WISeQey cryptographic Root of Trust, WISeQey provides secure authentication and identification for IoT, blockchain, and AI applications. The WISeQey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeQey’s strategic direction and its subsidiary companies, please visit www.wisekey.com.

About SEALSQ:
SEALSQ is a leading innovator in Post-Quantum Technology hardware and software solutions. Our technology seamlessly integrates Semiconductors, PKI (Public Key Infrastructure), and Provisioning Services, with a strategic emphasis on developing state-of-the-art Quantum Resistant Cryptography and Semiconductors designed to address the urgent security challenges posed by quantum computing. As quantum computers advance, traditional cryptographic methods like RSA and Elliptic Curve Cryptography (ECC) are increasingly vulnerable.

SEALSQ is pioneering the development of Post-Quantum Semiconductors that provide robust, future-proof protection for sensitive data across a wide range of applications, including Multi-Factor Authentication tokens, Smart Energy, Medical and Healthcare Systems, Defense, IT Network Infrastructure, Automotive, and Industrial Automation and Control Systems. By embedding Post-Quantum Cryptography into our semiconductor solutions, SEALSQ ensures that organizations stay protected against quantum threats. Our products are engineered to safeguard critical systems, enhancing resilience and security across diverse industries.

For more information on our Post-Quantum Semiconductors and security solutions, please visit www.sealsq.com.

About WISeSat

WISeSat is a space technology company focused on secure satellite communications for Internet of Things applications. Its approach combines satellite infrastructure with cybersecurity and digital identity technologies to support trusted communications between connected devices and ground-based systems.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding estimation of the listing. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of WISeSat’s management and are not predictions of actual performance. These statements involve risks, uncertainties and other factors that may cause the actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although WISeSat believes that it has a reasonable basis for each forward-looking statement contained in this press release, WISeSat cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. The forward-looking statements in this press release represent the views of WISeSat as of the date of this press release. Subsequent events and developments may cause those views to change. Except as may be required by law, WISeSat does not undertake any duty to update these forward-looking statements.

CONTACTS

WISeSat:
Carlos Moreira
Chairman & CEO
Tel: +41 22 594 3000
info@wisesat.com

WISeSat Investor Relations:
The Equity Group Inc.
Lena Cati
Tel: +1 212 836-9611
Lena.cati@theequitygroup.com